Roger Blumenthal, Pamela B. Morris
8 min
The American College of Cardiology and the American Heart Association have released updated, consolidated guidelines for managing dyslipidemia. With one in four U.S. adults affected by high low-density lipoprotein-cholesterol (LDL-C), these recommendations aim to standardize the approach to assessing and treating blood lipids to mitigate the risk of atherosclerotic cardiovascular disease (ASCVD). The document emphasizes a proactive stance, prioritizing healthy lifestyle modifications as the first line of defense while lowering the threshold for initiating lipid-lowering medications.
A central component of the new guidance is the adoption of the Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) calculator. This tool is designed to replace older models, such as the Pooled Cohort Equations, which were found to overestimate 10-year risk by 40% to 50%. The PREVENT-ASCVD equations provide a more contemporary estimate of cardiovascular risk for adults aged 30 to 79. By integrating personal health data—including blood pressure and cholesterol levels—along with specific 'risk enhancers' like chronic inflammatory conditions or family history, clinicians can now create more personalized treatment plans.
The guideline reaffirms the principle that 'lower is better' regarding LDL-C levels. It reinstates specific numerical targets for different risk groups: less than 100 mg/dL for borderline or intermediate risk, and less than 70 mg/dL for high-risk individuals. For those at very high risk, the target is tightened to below 55 mg/dL. When lifestyle interventions and statins are insufficient, the guideline supports the introduction of non-statin therapies, such as ezetimibe, bempedoic acid, or PCSK9 inhibitors, to help patients reach these lower targets more effectively.
To refine risk stratification for individuals where the need for treatment remains ambiguous, the guideline supports selective use of advanced diagnostic tools. These include non-contrast coronary artery calcium (CAC) scans, which can identify subclinical plaque buildup, and the measurement of lipoprotein(a), which remains a stable, genetically determined marker of long-term risk. Additionally, the guideline advocates for early cholesterol screening in children aged 9 to 11 to address inherited risks at the earliest possible stage.
Sam: That's a long list. Is there anything more objective than history and diagnoses?
Alex: Yes, and that's where selected tests come in. One example makes it concrete. Take a man aged 40 or older, or a woman 45 or older, at borderline or intermediate risk. If it would help decide on a statin, the guideline recommends a coronary artery calcium scan. It's a non-contrast scan that looks for calcium and plaque in the heart's arteries. Any calcium at all supports an LDL goal below 100. More calcium supports a lower target.
Sam: So the scan doesn't replace the calculator. It settles the cases where the calculator leaves you on the fence.
Alex: That's how the release frames it: for when there remains uncertainty about a person's true risk.
Sam: You mentioned targets. I had the impression numeric LDL goals had fallen out of favour at some point.
Alex: The release says LDL and non-HDL goals are "back," without explaining the history. For a first event, the goal is below 100 for borderline or intermediate risk, and below 70 for high risk. For people who already have heart disease and are at very high risk, the goal is below 55.
Sam: What's the case for pushing that low?
Alex: The vice-chair, Pamela Morris, says clinical trials have shown significant benefit at LDL levels lower than earlier guidelines recommended. Blumenthal compares it to blood pressure: lower for longer gives much greater protection. He also says medication should be considered earlier than ten years ago, if lifestyle changes alone don't get the numbers into range.
Sam: Lifestyle first, then drugs sooner than before. What's the drug ladder once a statin isn't enough?
Alex: Statins stay the foundation. If LDL still isn't low enough, the guideline adds non-statin options, depending on risk. Those include ezetimibe and a newer oral drug called bempedoic acid. There's also an injectable antibody class known as PCSK9 inhibitors. A fourth option, inclisiran, needs fewer injections. But the release says it's still being studied, to see whether its LDL lowering actually means fewer cardiac events.
Sam: There was another blood marker in there I wanted to ask about, lipoprotein little a.
Alex: Right. It's a cholesterol-carrying particle whose level is largely set by your genes and stays fairly stable for life. The guideline says to measure it at least once in adulthood. A high level is associated with about a 1.4-fold higher long-term risk of heart attack or stroke. Lifestyle barely moves it, so repeat testing generally isn't needed.
Sam: That fits Blumenthal's point that a good LDL number isn't a free pass.
Alex: Exactly his phrase, a "get out of jail free" card. A related marker, apolipoprotein B, can help assess remaining risk. That applies to people with diabetes, high triglycerides, or existing heart disease who've already hit their LDL goals. The release says it may be more accurate than LDL in those groups.
Sam: Does it say anything about specific groups, beyond the general adult population?
Alex: A few. It recommends starting lipid-lowering therapy at 40 or older for people with chronic kidney disease, HIV, or diabetes. It says to continue therapy during cancer treatment unless there's a reason not to. And it says to defer most of these drugs during conception, pregnancy and breastfeeding. It also recommends cholesterol screening for all children aged 9 to 11 who haven't been screened before.
Sam: Now the trust question. How strong is the evidence behind all this?
Alex: From this document, we can't really tell. A guideline from eleven organizations carries weight. But the press release shows no trial data, no evidence grades, and no strength rating for each recommendation. The claim that older calculators overestimated risk comes from the chair, without numbers on the data behind it. And the inclisiran point shows the authors drawing a line between lowering LDL and proving fewer events.
Sam: So the direction is clear, but the weight behind each recommendation lives in the full text.
Alex: That's my read, yes.
Sam: Then who should actually sit down with the full guideline, and where should they start?
Alex: Clinicians in primary care, cardiology and prevention, and anyone researching cardiovascular risk. Start with how the PREVENT risk bands map onto treatment and LDL goals. Then read the sections on calcium scanning and lipoprotein little a, since those change everyday practice. Check the evidence grade on each recommendation, which this release doesn't give you.
Sam: And for everyone else, the one line to keep?
Alex: Measure risk better, then get LDL down earlier and keep it down longer.
Sam: Simple advice, now with a better way to aim it.